Show simple item record

Real-world analysis of the impact of pemetrexed in firstline maintenance (1LM) with immunotherapy (IO) for non-squamous (NSQ) advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking targetable mutations, prior to and during the COVID-19 pandemic

dc.contributor.authorFabio, Gomesen
dc.contributor.authorNiall, G.en
dc.contributor.authorVivian, T.en
dc.contributor.authorKaterina, C.en
dc.contributor.authorJoanne, R.en
dc.contributor.authorAmine, A.en
dc.contributor.authorAdam, J.en
dc.contributor.authorAnna, M.en
dc.date.accessioned2024-07-08T15:12:48Z
dc.date.available2024-07-08T15:12:48Z
dc.date.issued2024en
dc.identifier.citationFabio G, Niall G, Vivian T, Katerina C, Joanne R, Amine A, et al. Real-world analysis of the impact of pemetrexed in firstline maintenance (1LM) with immunotherapy (IO) for non-squamous (NSQ) advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking targetable mutations, prior to and during the COVID-19 pandemic. Lung cancer (Amsterdam, Netherlands). 2024 APR;190:52-. PubMed PMID: WOS:001231921600001. English.en
dc.identifier.doi10.1016/j.lungcan.2024.107662en
dc.identifier.urihttp://hdl.handle.net/10541/627014
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.lungcan.2024.107662en
dc.titleReal-world analysis of the impact of pemetrexed in firstline maintenance (1LM) with immunotherapy (IO) for non-squamous (NSQ) advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking targetable mutations, prior to and during the COVID-19 pandemicen
dc.typeArticleen
dc.contributor.departmentThe Christie Hospital, Manchester, United Kingdomen
dc.identifier.journalLung Canceren
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record